Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mCOFLU
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
mCOFLU (mRNA-1083) is a combination mRNA vaccine developed by Moderna that targets both seasonal influenza and COVID-19. It is formulated in lipid nanoparticles and contains five mRNA sequences: four encoding the membrane-bound hemagglutinin (HA) glycoproteins of seasonal influenza virus strains (A/H1N1, A/H3N2, B/Victoria, and B/Yamagata) and one encoding the linked N-terminal domain (NTD) and receptor-binding domain (RBD) of the SARS-CoV-2 spike glycoprotein (specifically the Omicron XBB.1.5 variant). The vaccine is designed for active immunization of adults aged 50 and older. In clinical trials, mCOFLU demonstrated robust immunogenicity, eliciting non-inferior or superior antibody responses compared to co-administered licensed influenza and COVID-19 vaccines.
- Brand names
- mCOFLUmCOMBRIAX
- Other names
- Combined Influenza and COVID-19 mRNA vaccineInfluenza and COVID-19, mRNA vaccineinfluenza mRNA vaccine; COVID-19 mRNA vaccinemRNA-1083 vaccinemRNA1083 vaccinemRNA 1083 vaccine
02
Targets
HA (Hemagglutinin)SARS-CoV-2 spike
Beyond the preview
Go deeper on mCOFLU.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mCOFLU.